UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):       January 16, 2020
INTELGENX TECHNOLOGIES CORP.
(Exact Name of Registrant as Specified in Charter)

Delaware	 	000-31187	 	870638336	
(State or Other Jurisdiction
of Incorporation)	 	(Commission
File Number)	 	(I.R.S. Employer
Identification No.)	
6420 Abrams
Ville St-Laurent, Quebec, Canada H4S 1Y2
(Address of Principal Executive Offices, and Zip Code)
(514) 331-7440
Registrant's Telephone Number, Including Area Code
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 	[   ]	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	

 	[   ]	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	

 	[   ]	Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	

 	[   ]	Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered	
Common Stock, $0.00001 par value	IGXT
IGX	OTCQX
TSX Venture Exchange	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.
In connection with IntelGenx Technologies Corp.'s (the "Corporation") Registration Statement on Form S-1 (File No.333-235607), the Corporation intends to use the term sheet attached hereto as Exhibit 99.1, which is incorporated by reference herein.
Item 9.01. Exhibits.

Exhibit	Description	
99.1	Term Sheet dated January 16, 2020	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 	INTELGENX TECHNOLOGIES CORP.
(Registrant)	

Dated: January 16, 2020	By: /s/ Horst G. Zerbe
Horst G. Zerbe
President and Chief Executive Officer	

TERM SHEET
INTELGENX TECHNOLOGIES CORP.
OFFERING OF UNITS
JANUARY 16, 2020
The issuer has filed a registration statement (including a prospectus) with the United States Securities and Exchange Commission ("SEC") for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the issuer, the agent or any dealer participating in the offering will arrange to send you the prospectus, as supplemented, if you request it by contacting Echelon Wealth Partners Inc., attention: Beth Shaw, Head of Equity Capital Markets, 1 Adelaide Street East, Suite 2100, Toronto, ON, M5C 2V9, email: ecm@echelonpartners.com.
A preliminary short form prospectus containing important information relating to the securities described in this document has been filed with the securities regulatory authorities in the provinces of British Columbia, Alberta, Manitoba, Ontario and Quebec. A copy of the preliminary short form prospectus, and any amendment, is required to be delivered with this document. The preliminary short form prospectus is still subject to completion. There will not be any sale or any acceptance of an offer to buy the securities until a receipt for the final short form prospectus has been issued.
This document does not provide full disclosure of all material facts relating to the securities offered. Investors should read the preliminary short form prospectus, the final short form prospectus and any amendment for disclosure of those facts, especially risk factors relating to the securities offered, before making an investment decision.

Issuer:	IntelGenx Technologies Corp.  (the "Corporation").	
 	 	
Issue:	Treasury offering of units (each, a "Unit"), with each Unit comprised of one share of common stock in the Corporation (each, a "Share"), and one half of one share purchase warrant (each whole share purchase warrant, a "Warrant") (the "Offered Securities").	
 	 	
Issue Price:	C$• per Unit.	
 	 	
Issue Size:	Minimum aggregate gross proceeds of C$5,000,000 and maximum aggregate gross proceeds of C$10,000,000 (the "Offering").	
 	 	
Over-Allotment Option:	The Corporation will grant the Agent (as defined herein) an option to increase the size of the Offering by up to 15.0% of the number of Units offered, exercisable in whole or in part at any time for a period of 30 days after and including the Closing Date (the "Over-Allotment Option").	

Warrants:	Each Warrant entitles the holder thereof to acquire one Share for an exercise price of C$• per Share for a period of • months following the Closing Date.	
 	 	
Form of Offering:	The Units will be offered by way of a short-form prospectus exclusively in British Columbia, Alberta, Manitoba, and Ontario.	
 	 	
Use of Proceeds:	The Corporation intends to use the net proceeds of the Offering for the Phase 2A Montelukast Study, general working capital requirements, and manufacturing facility expansion. The Corporation intends to use any additional proceeds received from the exercise of the Over-Allotment Option or any of the Warrants or Agent's Warrants (as defined herein) to advance other existing projects and for working capital purposes.	
 	 	
Listing:	The Corporation will apply to list the Shares issuable pursuant to the Offering on the TSXV. Listing will be subject to the Corporation fulfilling all of the applicable listing requirements of the TSXV.	
 	 	
Eligibility:	The Shares and Warrants shall be eligible for RRSPs, RRIFs, RDSPs, RESPs, TFSAs, and DPSPs.	
 	 	
Agent:	Echelon Wealth Partners Inc. (the "Agent").	
 	 	
Agent Fee:	The Corporation will pay to the Agent, on the Closing Date, a cash commission equal to 7.0% of the aggregate gross proceeds received from the sale of the Offered Securities. In addition, the Corporation shall issue warrants to the Agent (the "Agent's Warrants") equal to 7.0% of the Offered Securities sold in the Capital Raising Transaction (including the Over-Allotment Option). Each Agent's Warrant entitles the holder thereof to acquire one Share for an exercise price of C$• per Share for a period of • months following the Closing Date; provided that such commissions shall be reduced to 3.5% in respect of any Units sold to purchasers on the "President's List" (collectively, the "Capital Raising Commission").	
 	 	
Closing Date:	•, 2020, or such other date as the Corporation and the Agent may agree (the "Closing Date").